Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShares IssuedShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBPP) Change in Account Payables (2016 - 2025)

Regen BioPharma (RGBPP) has disclosed Change in Account Payables for 13 consecutive years, with -$31640.0 as the latest value for Q4 2025.

  • On a quarterly basis, Change in Account Payables changed 0.0% to -$31640.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $821.0, a 94.57% decrease, with the full-year FY2025 number at $821.0, changed N/A from a year prior.
  • Change in Account Payables was -$31640.0 for Q4 2025 at Regen BioPharma, down from $95741.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $95741.0 in Q3 2025 to a low of -$112037.0 in Q3 2023.
  • A 5-year average of -$11365.7 and a median of -$12816.5 in 2021 define the central range for Change in Account Payables.
  • Biggest YoY gain for Change in Account Payables was 37008.91% in 2025; the steepest drop was 25804.19% in 2025.
  • Regen BioPharma's Change in Account Payables stood at -$31640.0 in 2021, then skyrocketed by 107.08% to $2240.0 in 2022, then tumbled by 2187.81% to -$46767.0 in 2023, then soared by 32.35% to -$31640.0 in 2024, then changed by 0.0% to -$31640.0 in 2025.
  • Per Business Quant, the three most recent readings for RGBPP's Change in Account Payables are -$31640.0 (Q4 2025), $95741.0 (Q3 2025), and -$98954.0 (Q2 2025).